AdvanSix Wins a Grant, Loses Another Year on the Cash It Was Promised
A $47M USDA award for Project CENTURY is real, new, and years from producing — while sulfur, fixed-cost absorption and a drifting 45Q refund keep the near-term spread hostage
ASIX · Earnings Call · 2026-11-04
The quarter pricing rescued, and fixed costs undid
AdvanSix sold $431 million of product in the third quarter, up 15% year-on-year, and the mechanism was almost purely price: 17% favorable pricing against a 2% volume decline, split between 10 points of raw-material pass-through and 7 points of market-based pricing that rose across every product line. “we generated 15% sales growth year-over-year as our teams continued to leverage both formula and market-based pricing mechanisms to offset inflationary raw material costs” — Erin Kane, President and CEO · 2026-11-04 That is genuinely good commercial execution in a commodity chain, and it is also entirely defensive. “Raw material costs were our largest headwind in the quarter of $65 million.” — Patrick Day, Senior Vice President and CFO · 2026-11-04 Adjusted EBITDA of $15 million was down $10 million year-on-year; adjusted EPS was a loss of $0.24. The offset that pricing could not reach was operational: reduced production at Hopewell and Frankford produced unfavorable fixed cost absorption, booking as an $8 million "all other" drag. The company's own framing — that its core caprolactam operating rate still beats global industry averages by nearly 10% — is true and beside the point. Running better than a broken industry is not the same as running well. As Erin Kane put it on the call, “we're probably 8%-10% below where we would have been when the markets are a bit healthier” — Erin Kane, President and CEO · 2026-11-04. Gross margin of 7.4% in the last reported quarter tells the same story from the other direction: this is a business whose profitability is set by the spread between what it pays for molecules and what it can charge, and that spread has compressed hard. Revenue of $421 million in the most recent 10-Q, meanwhile, has gone almost nowhere in eleven years: up 26% cumulatively, and 21% below the 2022 peak quarter.Project CENTURY is the one thing that is actually new
Everything else on this call had a familiar ring. The one item that did not is Project CENTURY — AdvanSix was selected as one of eight projects to receive $47 million in proposed USDA FIELDS Program funding against a planned $98 million, multi-year investment through 2031 that modernizes and expands ammonia at Hopewell, adding roughly 84,000 tons of annual ammonia output. Management claims the structure supports an internal rate of return above its 20% hurdle for discretionary capital.The delta matters because three months ago this was an application, not an award. On the August call Kane described the program as one “which we are planning to apply for relative to our ammonia to expand our ammonia capacity” — Erin N. Kane, President and CEO · 2026-08-07. Going from applicant to one-of-eight is a real milestone — and the keyword trajectory agrees, with Project CENTURY arriving at the very top of the company's keyword set in the current quarter, unseating the SUSTAIN program that had dominated the narrative all year. But the sequencing is where the analyst pushback landed, and rightly. 2027 preliminary capital planning is around $80 million for base capital plus the final SUSTAIN project; CENTURY's peak spend is 2029–2031; the DEF project's final investment decision sits in Q2 2027; and the capacity release from all of it arrives years out. Kane was explicit that the company is committed to a well-managed balance sheet — a phrase that reads very differently against effective net cash of -$268 million.AdvanSix was selected to receive $47 million in proposed funding through the USDA FIELDS Program in support of our Project CENTURY, or Capacity Expansion for Nitrogen Technology, U.S. Resilience, and Yield. We were one of eight projects selected under this program.
Sulfur: the relief that keeps arriving next quarter
The single largest swing factor in the model is sulfur cost, and management has now spent at least four consecutive quarters promising its normalization. The Tampa marker was $705 per long ton in Q3 and settled at $615 for Q4 — progress, but from a near-twenty-year high, and the sensitivity is brutal: “every $100 per ton per long ton change in sulfur price equals an approximately $35 million cost impact on an annualized basis” — Erin Kane, President and CEO · 2026-11-04. Against $15 million of quarterly EBITDA, that is the whole ballgame. The history is the tension. In February, Kane framed sulfur as a market that always mean-reverts:Six months later it was $705. That is not a management credibility problem in the ordinary sense — the direction has finally turned. But it does mean the entire 2027 earnings recovery thesis rests on an input-cost variable AdvanSix does not control, in a business where the company freely concedes there is some lag in realized input pricing. The bull case, fairly stated, is supply: several North American ammonium sulfate producers are curtailed, and the market looks short into spring 2027.We are sitting at nearly 20-year highs for sulfur prices right now... a similar type surge has happened twice before, 2008 and 2022, and in both times, prices dropped precipitously in the following sort of six months.